Machine signal
Active cluster sell — 5 distinct insiders, $21.4M, window ends Oct 1, 2026.
Figures computed from official regulatory filings — .
Analysttarget 155 USD (+84%) · consensus 4.85/5 · 13 buy · 0 hold · 0 sell
Ownershipinsiders 1.26% · institutions 116.55% · short 16.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Oruka Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
63 buys207 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Klein Lawrence Otto | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klein Lawrence Otto | Sell | $17K | SEC |
| Klein Lawrence Otto | Sell | $1.4M | SEC |
| Klein Lawrence Otto | Exercise | $195K | SEC |
| Klein Lawrence Otto | Sell | $718.8K | SEC |
| Quinlan Paul T | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Quinlan Paul T | Sell | $254.2K | SEC |
| Agarwal Arjun | Sell | $51K | SEC |
| Quinlan Paul T | Exercise | $78K | SEC |
| Quinlan Paul T | Sell | $56.8K | SEC |
| Quinlan Paul T | Sell | $357.6K | SEC |
| Quinlan Paul T | Sell | $267.9K | SEC |
| Goncalves Joana | Sell | $127K | SEC |
| Goncalves Joana | Exercise | $23.9K | SEC |
| Goncalves Joana | Sell | $217.2K | SEC |
| Goncalves Joana | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Agarwal Arjun | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klein Lawrence Otto | Sell | $234.7K | SEC |
| Agarwal Arjun | Exercise | $50.2K | SEC |
| Goncalves Joana | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Goncalves Joana | Sell | $90.6K | SEC |
| Agarwal Arjun | Exercise | $100K | SEC |
| Agarwal Arjun | Sell | $273.3K | SEC |
| Goncalves Joana | Exercise | $27.3K | SEC |
| Agarwal Arjun | Sell | $205.9K | SEC |